Identification of and discrimination between the Mycobacterium abscessus complex and Mycobacterium avium complex directly from sputum using quadruplex real-time PCR.

Introduction. Cystic fibrosis (CF) is a serious disease with multisystemic clinical signs that is easily and frequently complicated by bacterial infection. Recently, the prevalence of nontuberculous mycobacteria as secondary contaminants of CF has increased, with the Mycobacterium avium complex (MAC) and Mycobacterium abscessus complex (MABSC) being the most frequently identified. The MABSC includes subspecies of significant clinical importance, mainly due to their resistance to antibiotics.Gap statement. Sensitive method for early detection and differentiation of MABSC members and MAC complex for use in routine clinical laboratories is lacking. A method based on direct DNA isolation from sputum, using standard equipment in clinical laboratories and allowing uncovering of possible sample inhibition (false negative results) would be required. The availability of such a method would allow accurate and accelerated time detection of MABSC members and their timely and targeted treatment.Aim. To develop a real time multiplex assay for rapid and sensitive identification and discrimination of MABSC members and MAC complex.Methodology. The method of DNA isolation directly from the sputum of patients followed by quadruplex real-time quantitative PCR (qPCR) detection was developed and optimised. The sensitivity and limit of detection (LOD) of the qPCR was determined using human sputum samples artificially spiked with a known amount of M. abscessus subsp. massiliense (MAM).Results. The method can distinguish between MAC and MABSC members and, at the same time, to differentiate between M. abscessus subsp. abscessus/subsp. bolletii (MAAb/MAB) and MAM. The system was verified using 61 culture isolates and sputum samples from CF and non-CF patients showing 29.5 % MAAb/MAB, 14.7 % MAM and 26.2 % MAC. The LOD was determined to be 1 490 MAM cells in the sputum sample with the efficiency of DNA isolation being 95.4 %. Verification of the qPCR results with sequencing showed 100 % homology.Conclusions. The developed quadruplex qPCR assay, which is preceded by DNA extraction directly from patients' sputum without the need for culturing, significantly improves and speeds up the entire process of diagnosing CF patients and is therefore particularly suitable for use in routine laboratories.

[1]  J. Lipuma,et al.  Cystic fibrosis airway microbiota associated with outcomes of nontuberculous mycobacterial infection , 2021, ERJ Open Research.

[2]  K. De Boeck.  Cystic fibrosis in the year 2020: A disease with a new face , 2020, Acta paediatrica.

[3]  L. Chiarelli,et al.  Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients , 2019, International journal of molecular sciences.

[4]  R. Master,et al.  Current significance of the Mycobacterium chelonae-abscessus group. , 2019, Diagnostic microbiology and infectious disease.

[5]  C. Ren,et al.  Review of Cystic Fibrosis. , 2019, Pediatric annals.

[6]  Chang Ki Kim,et al.  Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. , 2019, Diagnostic microbiology and infectious disease.

[7]  R. Arbeit,et al.  Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41) , 2018, The Journal of antimicrobial chemotherapy.

[8]  Radhey S. Gupta,et al.  Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera , 2018, Front. Microbiol..

[9]  Jong Hyuk Lee,et al.  Implication of species change of Nontuberculous Mycobacteria during or after treatment , 2017, BMC Pulmonary Medicine.

[10]  K. Chew,et al.  Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. , 2017, Journal of medical microbiology.

[11]  Y. Kook,et al.  Allele-specific duplex polymerase chain reaction to differentiate Mycobacterium abscessus subspecies and to detect highly clarithromycin-resistant isolates , 2016, Indian journal of medical microbiology.

[12]  L. Raskin,et al.  Culture-Independent Identification of Nontuberculous Mycobacteria in Cystic Fibrosis Respiratory Samples , 2016, PloS one.

[13]  Emily A. Knapp,et al.  Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. , 2016, Chest.

[14]  R. Gibson,et al.  US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary , 2015, Thorax.

[15]  T. Shim,et al.  Separation of Mycobacterium abscessus into subspecies or genotype level by direct application of peptide nucleic acid multi-probe- real-time PCR method into sputa samples , 2015, BMC Infectious Diseases.

[16]  D. Whiley,et al.  Identification of Mycobacterium abscessus complex and M. abscessus subsp. massiliense culture isolates by real-time assays. , 2015, Journal of medical microbiology.

[17]  D. Taylor-Robinson,et al.  Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  E. Böttger,et al.  Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. , 2014, The Journal of antimicrobial chemotherapy.

[19]  Young Kil Park,et al.  The Drug Resistance Profile of Mycobacterium abscessus Group Strains from Korea , 2013, Annals of laboratory medicine.

[20]  G. Bloemberg,et al.  Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). , 2012, The Journal of antimicrobial chemotherapy.

[21]  B. Gicquel,et al.  Mycobacterium abscessus: a new antibiotic nightmare. , 2012, The Journal of antimicrobial chemotherapy.

[22]  R. Whitlock,et al.  Development of a predictive model for detection of Mycobacterium avium subsp. paratuberculosis in faeces by quantitative real time PCR. , 2011, Veterinary microbiology.

[23]  I. Pavlik,et al.  On-farm spread of Mycobacterium avium subsp. paratuberculosis in raw milk studied by IS900 and F57 competitive real time quantitative PCR and culture examination. , 2008, International journal of food microbiology.

[24]  M. Bartoš,et al.  Strategy for the detection and differentiation of Mycobacterium avium species in isolates and heavily infected tissues. , 2008, Research in veterinary science.

[25]  I G Wilson,et al.  Inhibition and facilitation of nucleic acid amplification , 1997, Applied and environmental microbiology.

[26]  S. Wilton,et al.  Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube. , 1992, PCR methods and applications.

[27]  V. Lévy-Frébault,et al.  Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of Mycobacterium avium, and description of Mycobacterium avium subsp. avium subsp. nov., Mycobacterium avium subsp. paratuberculosis subsp. nov., and Mycobacterium avium subsp. silvaticum subsp. nov. , 1990, International journal of systematic bacteriology.

[28]  S. Hananya,et al.  Increasing nontuberculous mycobacteria infection in cystic fibrosis. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[29]  I. Pin,et al.  Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[30]  D. van Soolingen,et al.  Mycobacterium avium in a shower linked to pulmonary disease , 2008 .